Short answer
AVANOS MEDICAL, INC. (AVNS) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Avanos received all required regulatory approvals for its pending acquisition by American Industrial Partners affiliates.
AVANOS MEDICAL, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Avanos received all required regulatory approvals for its pending acquisition by American Industrial Partners affiliates
- Regulatory clearance removes a key closing condition, materially increasing transaction completion certainty
- Press release dated July 2, 2026 provides additional closing details in Exhibit 99.1
Item EX-99.1 · Exhibit EX-99.1
- All required regulatory approvals received, removing a major condition for AIP’s pending acquisition of Avanos
- Stockholder vote scheduled July 22, 2026, at 9:00 a.m. Eastern time
- Transaction expected to close by July 27, 2026, subject to stockholder approval and remaining customary conditions
- Key remaining risks include unmet closing conditions, competing proposals, or potential termination fees
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other AVANOS MEDICAL, INC. 8-K filings
Get the next AVNS 8-K as it lands
Follow AVNS for push alerts, or ask the research agent what this filing means.